COVID-19 Turmoil Dents Biocon In Q4 But Opportunities Including Glargine In Store

Biocon’s fourth quarter earnings were impacted by pandemic-related disruptions, especially its biologics arm, but the Indian firm anticipates a “good recovery”. All eyes will be on the anticipated US launch of biosimilar insulin glargine and its interchangeability status, while the company remains confident of delivering a $1bn FY2022 revenue target for biologics.